TABLE III.

Multivariate Analysis of Clinical Outcomes

	OS				TRM			RR
	N	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
Treatment group
Poor-risk: chemotherapya	109	1			1			1
Poor-risk: MRD	49	1.08	0.65–1.80	0.76	1.32	0.38–4.62	0.66	0.82	0.50–1.34	0.42
Poor-risk: URD	47	1.13	0.66–1.92	0.67	2.66	0.93–7.62	0.07	0.43	0.23–0.81	0.01
Race
Not African Americana	178	1			1			1
African American	27	2.02	1.20–3.40	0.009	1.35	0.32–5.75	0.69	2.01	1.22–3.30	0.01
Age at diagnosis
3–11 yoa	72	1			1			1
0–2 yo	64	0.94	0.56–1.55	0.80	0.66	0.19–2.26	0.51	0.98	0.60–1.58	0.92
12–21 yo	69	1.45	0.92–2.29	0.11	2.01	0.85–4.73	0.11	0.94	0.58–1.54	0.82
WBC at diagnosis
<50,000a	179	1			1			1
≥50,000	26	1.54	0.90–2.65	0.12	0.65	0.12–3.37	0.61	1.52	0.81–2.86	0.19
Time period
1989–1997a	89	1			1			1
1998–2006	116	0.90	0.61–1.34	0.62	0.94	0.41–2.15	0.88	0.84	0.57–1.25	0.39

OS, overall survival; TRM, treatment-related mortality; RR, relapse risk; HR, hazard ratio; CI, confidence interval; MRD, matched related donor; URD, unrelated donor; yo, years old.

^aIdentifies reference group.